Biomedical Research

Purpose: Cisplatin (Cis) is a commonly used cancer treatment drug, particularly in breast cancer. Nevertheless, the side effects of Cis have an impact on other body systems. This study aims to investigate the therapeutic potential of Ellagic acid (Ell) to alleviate the side effects of Cis.

Methods: Forty male albino rats were randomly divided into four groups: the Control group, Cis group, Ell group, and Cis+Ell group. To evaluate neurotransmitters, biochemical estimations of liver function, urea, creatinine, BUN, and brain tissue homogenates were performed. The liver and kidney slices from all groups were processed for histopathological and immunohistochemical analyses.

Results: Our studies proved that Ell caused a significant improvement in the antioxidant enzymes, MDA level, and both liver and kidney functions and disturbance in GABA and glutamate levels in brain homogenates after the negative effects induced by Cis. Ell also reduced cleavage of caspase 3 and immunoreactivity of COX2 in the kidneys of Cis-treated rats, increased expression of antiapoptotic Bcl2 in and suppressed the expression of P53 in the hepatocytes, and reduced cleavage of caspase 3 and the immunoreactivity of COX2 in the kidney of Cis-treated rats.

Conclusion: Treatment with Ell can effectively mitigate the negative effects on liver, kidney and brain that are caused by the administration of Cis.

Author(s): Hani M. Abdelsalam, Abdelaziz A Diab, Atef G Hussein, Nourhan I Gomaa, Josef A Aziz
Abstract | Full-Text | PDF

Share this